Managing Coagulation Abnormalities, Bleeding, and Thrombosis in Patients with Cirrhosis

Area of Science:

• Hepatology
• Hematology
• Clinical Medicine

Background:

• Cirrhosis disrupts the balance of procoagulant and anticoagulant factors, complicating hemostasis.
• Managing bleeding and thromboembolism in cirrhosis patients presents significant clinical challenges.
• Traditional coagulation tests lack accuracy in assessing hemostasis in cirrhosis.

Purpose of the Study:

• To provide evidence-based guidance for clinical decision-making in managing hemostasis in cirrhosis.
• To clarify the role of laboratory tests and advanced diagnostics in bleeding risk assessment.
• To outline optimal strategies for anticoagulation in cirrhosis-associated thrombosis and atrial fibrillation.

Main Methods:

• Comprehensive review of contemporary literature on cirrhosis, hemostasis, and anticoagulation.
• Analysis of the utility of prothrombin time and activated partial thromboplastin time in cirrhosis.
• Evaluation of viscoelastometry for perioperative bleeding management.
• Assessment of anticoagulation strategies for portal vein thrombosis and atrial fibrillation.

Main Results:

• Prothrombin time and activated partial thromboplastin time are poor predictors of bleeding in cirrhosis.
• Patient and procedure-specific variables are more reliable for bleeding risk assessment.
• Viscoelastometry can guide transfusion product use during perioperative bleeding.
• Anticoagulation is crucial for portal vein thrombosis (≥50% obstruction) and atrial fibrillation, with direct oral anticoagulants as a preferred option.

Conclusions:

• Clinical assessment and advanced diagnostics are superior to standard coagulation tests for managing bleeding risk in cirrhosis.
• Direct oral anticoagulants are effective and recommended for treating portal vein thrombosis and atrial fibrillation in patients with cirrhosis.
• Prophylactic strategies for bleeding are rarely necessary; focus on risk assessment and targeted interventions.